Attovia Therapeutics (NASDAQ:ATTO) Stock Gets Price Target Boost from Morgan Stanley

Posted by James Quigley on Nov 10th, 2026

Attovia Therapeutics (NASDAQ:ATTO – Get Free Report) had its price target increased by Morgan Stanley from $39.00 to $40.00 in a research report issued on Tuesday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Morgan Stanley‘s price objective would indicate a potential upside of 144.65% from the company’s current price.

Several other equities analysts have also recently weighed in on the company. Leerink Partners initiated coverage on Attovia Therapeutics in a report on Monday, August 31st. They set an “outperform” rating and a $52.00 price objective on the stock. Royal Bank Of Canada initiated coverage on Attovia Therapeutics in a research note on Monday, August 31st. They set an “outperform” rating and a $45.00 target price for the company. Zacks Research upgraded shares of Attovia Therapeutics to a “hold” rating in a report on Friday, September 4th. Citigroup assumed coverage on shares of Attovia Therapeutics in a research note on Monday, August 31st. They issued a “buy” rating and a $30.00 price target on the stock. Finally, Lifesci Capital began coverage on shares of Attovia Therapeutics in a research report on Monday, August 31st. They set an “outperform” rating and a $45.00 price objective for the company. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Attovia Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $42.40.

Read Our Latest Analysis on ATTO

Attovia Therapeutics Trading Up 2.4%

Shares of NASDAQ ATTO traded up $0.39 during trading on Tuesday, reaching $16.35. The company had a trading volume of 37,507 shares, compared to its average volume of 345,904. Attovia Therapeutics has a 52 week low of $12.94 and a 52 week high of $28.00. The business’s 50 day moving average is $18.06. The stock has a market cap of $746.38 million and a PE ratio of -3.34.

Attovia Therapeutics (NASDAQ:ATTO – Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.02). The firm’s revenue for the quarter was down 100.0% on a year-over-year basis. During the same period last year, the company earned ($3.44) EPS. As a group, equities analysts expect that Attovia Therapeutics will post -4.06 EPS for the current year.